Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is evaluating of efficacy of innovative dietary strategy -stimulation of physiological ketosis with Liquid Technology Formula PanTrek, in patients with asthenia and or decreased tolerance to physical and\or mental exertion. PanTrek is a liquid formula of potassium and magnesium salts of beta-oxibutiric acid, ginsenosides and rosmarinic acid.
It will be double-blind, placebo-controlled study in 88 patients of both sex, aged from 18 to 65. Patients will be randomly assigned to one of two groups: placebo or IP group in 1:1 proportion. Study instruments: D-Fis, MoCA, TMT, VAS, assessment of blood keton concentration before and after first and last administration per os of 25 ml of placebo or PanTrek. PanTrek will be served in ampuls, 25 ml per ampule.
The duration of the study will be 15 days of treatment and 15 days of follow-up observation.
Patients will be assessed at screening/baseline, after 15 days and after 30 days.
The dose regimen: the shot of PanTrek, 25 ml, will be administered per os, twice per day, in the morning and in the evening, per se or deluted in 100 ml of water one hour before or after meal.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Placebo group | Placebo Comparator | Patients will recieve matched by taste and color shot of 25 ml liquid in ampules |
|
| Active treatment group | Experimental | Patients will recieve shot of PanTrek 25 ml in anpules |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| PanTrek | Dietary Supplement | administration of exogenouse keton body |
|
| Measure | Description | Time Frame |
|---|---|---|
| Primary outcome | Difference of changes of visual analog scale (VAS) indices between active treament and placebo groups. Minimum value - 0, maximum value - 100 scores. The higher score means the better condition. The major difference means better outcome. | 15 days |
| Measure | Description | Time Frame |
|---|---|---|
| indused ketosis | increase of ketons level from baseline to the end of the active treatment period of the study | 15 days |
| Measure | Description | Time Frame |
|---|---|---|
| Improvement in cognitive function | Difference in improvement in total scores of Montreal Cognitive Assessment (MoCA) between the treatment and placebo groups. Minimum value - 0, maximum value - 30 scores. The higher score means the better condition. The major difference means better outcome. | 15 days |
| Improvement in visual attention and task switching. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Denis Burminskiy, MD, PhD | Contact | +79262344633 | desbur@gmail.com | |
| Allan Beniashvili, MD, PhD | Contact | +79859259676 | beniashvilia@yandex.ru |
| Name | Affiliation | Role |
|---|---|---|
| Denis Burminskiy, MD, PhD | Mental health research center | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Laboratory of psychopharmacology Research center of mental health | Moscow | 115522 | Russia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D010358 | Patient Participation |
| D001247 | Asthenia |
| ID | Term |
|---|---|
| D010342 | Patient Acceptance of Health Care |
| D000074822 | Treatment Adherence and Compliance |
| D015438 | Health Behavior |
| D001519 | Behavior |
Not provided
Not provided
Not provided
Not provided
Not provided
randomized asignment to placebo or IP group, double-blind design
Difference in improvement of total time of Trial Making Test (TMT) execution between the treatment and placebo groups. Normal value - 29 seconds for A part and 75 seconds for B part. The higher time means worse condition. Decrease of spended time means improvement or negative score, if the last result is substractes from the first result, means improvement. |
| 15 days |
| Improvement in physical function | Difference in improvement in total scores of Daily Fatigue Investigation Scale (D-Fis) between the treatment and placebo groups. Minimum value - 0, maximum value - 32 scores. The higher score means the worse condition. The major difference means better outcome. | 15 days |
| Safety profile in active and follow-up period | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 on the first, 15th and 30th day. | 30 days |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |